What does metformin do

What It Is

Metformin is an oral antidiabetic medication belonging to the biguanide class of drugs. It works by helping your body use insulin more effectively and reducing the amount of glucose produced by your liver. Metformin is taken by mouth in tablet or liquid form, typically in doses ranging from 500 to 2,550 milligrams per day split into multiple doses. Unlike insulin injections, metformin allows the pancreas to produce its own insulin while improving how the body uses it.

Metformin was first synthesized in 1922 by chemists working with guanidine compounds derived from the French lilac plant. The medication was approved for use in France in 1957 and became available across Europe before the United States FDA approved it in 1995. A major landmark study called the Diabetes Prevention Program (1998-2001) demonstrated that metformin could reduce the risk of developing type 2 diabetes by 31% in people with prediabetes. Today, metformin is recommended as first-line therapy by the American Diabetes Association, the European Association for the Study of Diabetes, and the World Health Organization.

There are three main types of metformin formulations: immediate-release tablets taken two to three times daily, extended-release tablets taken once daily, and liquid suspension for those who cannot swallow pills. Immediate-release metformin begins working within hours, while extended-release formulations provide steadier blood sugar control throughout the day. Some patients use metformin in combination with other diabetes medications like sulfonylureas, GLP-1 agonists, or SGLT2 inhibitors when additional blood sugar control is needed. Generic metformin is available worldwide and costs significantly less than brand-name versions, making it accessible to patients in both developed and developing countries.

How It Works

Metformin reduces blood glucose through multiple mechanisms occurring primarily in the liver, kidneys, and muscle cells. The primary mechanism involves decreasing gluconeogenesis, which is the liver's process of creating new glucose from non-carbohydrate sources like amino acids and lactate. Metformin also improves insulin sensitivity by increasing glucose uptake in muscle and fat tissues, allowing cells to use available glucose more efficiently. Additionally, metformin may slow gastric emptying, reducing the rate at which food moves from the stomach to the small intestine, which moderates post-meal blood sugar spikes.

A practical example of metformin's mechanism can be seen in how Johnson & Johnson's clinical trials tracked patients at the Mayo Clinic and Johns Hopkins University. Researchers measured fasting glucose levels and hepatic glucose production in 200 patients before and after six weeks of metformin therapy at 2,000 mg daily. Participants showed an average 25-30% reduction in hepatic glucose output and improved muscle glucose uptake measured by glucose clamp studies. These clinical outcomes demonstrated that metformin's effects were consistent across different ethnic groups and body compositions, validating its use as a universal first-line therapy.

The practical implementation of metformin therapy typically begins with a low dose of 500 mg once or twice daily to allow the digestive system to adjust. After one to two weeks, doctors gradually increase the dose to the target amount, usually 1,000-2,000 mg daily split into two or three doses, based on kidney function and tolerance. Patients taking extended-release metformin usually take one dose of 1,500-2,000 mg with their evening meal, which reduces gastrointestinal side effects by minimizing peak drug levels. Regular blood tests measuring hemoglobin A1C every three months help doctors determine whether the current dose is achieving target blood sugar control or needs adjustment.

Why It Matters

Metformin has transformed diabetes management globally, with studies showing it prevents or delays type 2 diabetes onset by 31-35% in people with prediabetes. The Diabetes Prevention Program followed 3,234 participants for an average of 2.8 years and found that metformin-treated patients reduced their diabetes risk more effectively than lifestyle changes alone in certain populations. Over 220 million people worldwide have type 2 diabetes, and metformin is prescribed to approximately 65-70% of them, making it arguably the most important diabetes medication in modern medicine. The drug's proven safety profile over 70+ years of use has made it the standard first-line pharmacological treatment across every major healthcare system.

Metformin's applications extend beyond type 2 diabetes management across multiple medical specialties and patient populations. In obstetrics, the American College of Obstetricians and Gynecologists recommends metformin as first-line pharmacotherapy for polycystic ovary syndrome (PCOS), affecting approximately 10% of reproductive-age women and improving fertility outcomes in 40-50% of treated patients. Oncologists at leading cancer centers including Memorial Sloan Kettering have investigated metformin's potential anticancer properties, with studies showing reduced cancer risk in diabetes patients taking metformin compared to those taking other diabetes medications. Reproductive endocrinologists use metformin to improve ovulation rates and reduce miscarriage rates in women with PCOS, making it one of the most versatile medications in endocrinology.

The future of metformin therapy is expanding with emerging research into additional therapeutic applications and improved formulations. Scientists are investigating metformin's potential role in aging prevention and longevity, with ongoing clinical trials examining its effects on aging biomarkers in non-diabetic populations. Pharmaceutical companies are developing combination therapies pairing metformin with newer agents like SGLT2 inhibitors and GLP-1 agonists to provide superior cardiovascular and kidney protection. Extended-release formulations with improved tolerability and personalized dosing based on genetic testing are expected to further improve patient adherence and outcomes in the coming decade.

Common Misconceptions

A widespread misconception is that metformin damages the kidneys or is unsafe for people with kidney disease, but this belief oversimplifies the actual medical evidence. While metformin is contraindicated in severe kidney disease (eGFR less than 30 mL/min/1.73m²), patients with mild to moderate kidney impairment can safely use reduced doses of metformin with regular monitoring. Major medical organizations including the FDA and American Diabetes Association have updated guidelines to allow metformin use in patients with eGFR between 30-45, expanding safe use to millions of additional patients. The concern originated from rare cases of lactic acidosis in patients with unrecognized severe renal dysfunction in the 1970s-1980s, but modern renal monitoring has virtually eliminated this risk.

Another myth is that metformin causes vitamin B12 deficiency in all patients, when in reality only 10-30% of long-term users develop clinically significant deficiency requiring supplementation. The mechanism involves reduced calcium-dependent B12 absorption in the terminal ileum, but this occurs gradually and can be easily prevented with periodic B12 monitoring and supplementation when needed. Patients taking metformin should have B12 levels checked every 2-3 years, and those with low-normal levels can be started on B12 supplements or annual injections as a preventive measure. Most patients never develop deficiency symptoms, and those who do respond quickly to vitamin B12 supplementation without requiring metformin discontinuation.

A final misconception is that metformin will make diabetics hypoglycemic (dangerously low blood sugar), but metformin alone cannot cause hypoglycemia in properly selected patients. Unlike insulin and sulfonylurea drugs, metformin only works to lower glucose when blood sugar is elevated and does not stimulate the pancreas to produce excess insulin. Hypoglycemia occurs only when metformin is combined with insulin-secreting medications like sulfonylureas or insulin itself, and the risk is manageable through appropriate dose adjustment of the co-prescribed medication. This safety profile is one of the primary reasons metformin is the preferred first-line diabetes medication, as it provides effective glucose lowering without the hypoglycemia risk that deters many patients from taking other diabetes drugs.